Pond G - Search Results

1

Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study.

Awan AA, Saunders D, Pond G, Hamm C, Califaretti N, Mates M, Kumar V, Ibrahim MFK, Beltran-Bless AA, Vandermeer L, Hilton J, Clemons M. Awan AA, et al. Among authors: pond g. Curr Oncol. 2024 Feb 27;31(3):1278-1290. doi: 10.3390/curroncol31030096. Curr Oncol. 2024. PMID: 38534929 Free PMC article.

2

Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer.

Zhao H, Pond G, Simos D, Wang Z, Robertson S, Singh G, Vandermeer L, Clemons M, Addison CL. Zhao H, et al. Among authors: pond g. Cancers (Basel). 2023 Jan 17;15(3):571. doi: 10.3390/cancers15030571. Cancers (Basel). 2023. PMID: 36765529 Free PMC article.

3

Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study.

Aubrey C, Pond GR, Helpman L, Vicus D, Elit L, Plante M, Lau S, Kwon JS, Altman AD, Willows K, Feigenberg T, Sabourin J, Samouelian V, Bernard L, Cockburn N, Saunders NB, Piedimonte S, Teo-Fortin LA, Kim SR, Sadeq N, Jang JH, Shamiya S, Nelson G. Aubrey C, et al. Among authors: pond gr. Curr Oncol. 2023 Feb 6;30(2):1977-1985. doi: 10.3390/curroncol30020153. Curr Oncol. 2023. PMID: 36826114 Free PMC article.

4

Regularly scheduled physical examinations and the detection of breast cancer recurrences.

Beltran-Bless AA, Alshamsan B, Alzahrani MJ, Hilton J, Baines KA, Samuel V, Pond GR, Vandermeer L, Clemons M, Larocque G. Beltran-Bless AA, et al. Among authors: pond gr. Breast. 2023 Jun;69:274-280. doi: 10.1016/j.breast.2023.03.004. Epub 2023 Mar 8. Breast. 2023. PMID: 36922304 Free PMC article.

5

Can routinely collected administrative data effectively be used to evaluate and validate endpoints used in breast cancer clinical trials? Protocol for a scoping review of the literature.

Shah H, Wolfe D, Clemons M, Liu M, Thavorn K, Veroniki AA, Lunny C, Pond G, McGee S, Skidmore B, Arnaout A, Hutton B. Shah H, et al. Among authors: pond g. Syst Rev. 2023 Jul 8;12(1):117. doi: 10.1186/s13643-023-02283-5. Syst Rev. 2023. PMID: 37422656 Free PMC article.

6

Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets.

El Kababji S, Mitsakakis N, Fang X, Beltran-Bless AA, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow WE, Gralow J, Savard MF, Clemons M, El Emam K. El Kababji S, et al. Among authors: pond g. JCO Clin Cancer Inform. 2023 Sep;7:e2300116. doi: 10.1200/CCI.23.00116. JCO Clin Cancer Inform. 2023. PMID: 38011617 Free article.

7

Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective.

Bradbury M, Savard MF, Vandermeer L, Clemons L, Pond G, Hilton J, Clemons M, McGee S. Bradbury M, et al. Among authors: pond g. Curr Oncol. 2023 Dec 14;30(12):10477-10487. doi: 10.3390/curroncol30120763. Curr Oncol. 2023. PMID: 38132397 Free PMC article.

8

The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey.

Beltran-Bless AA, Larocque G, Brackstone M, Arnaout A, Caudrelier JM, Boone D, Fallah P, Ng T, Cross P, Alqahtani N, Hilton J, Vandermeer L, Pond G, Clemons M. Beltran-Bless AA, et al. Among authors: pond g. Breast Cancer Res Treat. 2024 Apr;204(3):531-538. doi: 10.1007/s10549-023-07232-3. Epub 2024 Jan 9. Breast Cancer Res Treat. 2024. PMID: 38194133

9

The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care.

Beltran-Bless AA, Clemons M, Vandermeer L, El Emam K, Ng TL, McGee S, Awan AA, Pond G, Renaud J, Barton G, Hutton B, Savard MF. Beltran-Bless AA, et al. Among authors: pond g. Curr Oncol. 2024 Mar 6;31(3):1376-1388. doi: 10.3390/curroncol31030104. Curr Oncol. 2024. PMID: 38534937 Free PMC article.

10

Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.

Bradbury M, Savard MF, Stober C, Clemons L, Clemons M, Hilton J, Pond G, Vandermeer L, McGee SF. Bradbury M, et al. Among authors: pond g. Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07302-0. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38664288

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

477 results

Search Page